Costly biologics have plan sponsors looking at benefit designs
More like this
- “White-bagging” creates difficulties for providers and patients
- Who Will Pay for High-Cost Biologics?
- New Hepatitis C drugs: A balancing act of costs and benefits
- The Affordable Care Act has reduced access to primary care physicians
- A Conversation With F. Randy Vogenberg, PhD, RPh: Changing Market for Pharmacy Benefits